- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12.11. | Zenas BioPharma, Inc. GAAP EPS of -$5.02 | 2 | Seeking Alpha | ||
| 12.11. | Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 144 | GlobeNewswire (Europe) | -INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma... ► Artikel lesen | |
| 12.11. | Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 115 | GlobeNewswire (Europe) | -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-... ► Artikel lesen | |
| 07.11. | Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences | 231 | GlobeNewswire (Europe) | WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the... ► Artikel lesen | |
| 08.10. | Zenas started at buy by four banks on lead drug potential | 2 | Seeking Alpha | ||
| 08.10. | Morgan Stanley bullisch für Zenas Biopharma-Aktie aufgrund zunehmender Dynamik bei obexelimab-Studien | 8 | Investing.com Deutsch | ||
| 08.10. | Citi sieht Aufwärtspotenzial für Zenas Biopharma-Aktie aufgrund von Fortschritten bei Obexelimab in wichtigen Studien | 3 | Investing.com Deutsch | ||
| 08.10. | Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials | 3 | Investing.com | ||
| 08.10. | Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum | 4 | Investing.com | ||
| 08.10. | Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials | 1 | Investing.com | ||
| 08.10. | Guggenheim setzt auf Zenas-Aktie aufgrund vielversprechender Aussichten für Hauptmedikament Obexelimab | 2 | Investing.com Deutsch | ||
| 08.10. | Jefferies zeigt sich bullisch für Zenas-Aktie aufgrund von Fortschritten bei Obexelimab in Autoimmun-Studien | 2 | Investing.com Deutsch | ||
| 08.10. | Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab | 2 | Investing.com | ||
| 21.09. | Zenas BioPharma CEO acquires $360k worth of company shares | 1 | Investing.com | ||
| 19.09. | Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering | 288 | GlobeNewswire (Europe) | WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas"), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and... ► Artikel lesen | |
| 18.09. | Zenas BioPharma director acquires $999k in company stock | 3 | Investing.com | ||
| 17.09. | IPO Radar: Applied Nutrition, Zenas BioPharma, BingEx | 2 | The Armchair Trader | ||
| 17.09. | Zenas BioPharma director buys $7.48m in company stock | 1 | Investing.com | ||
| 17.09. | Zenas BioPharma director Jason Raleigh acquires $15 million in company stock | 4 | Investing.com |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 254,15 | +0,20 % | Spotlight on Amgen: Analyzing the Surge in Options Activity | ||
| REGENERON PHARMACEUTICALS | 685,60 | -0,20 % | Sanofi and Regeneron's Dupixent, Leo Pharma's Anzupgo could help close treatment gap in chronic hand eczema: GlobalData | ||
| BIOMARIN PHARMACEUTICAL | 63,28 | -0,63 % | BioMarin: Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced positive and consistent results from multiple real-world evidence studies of VOXZOGO (vosoritide) in children with achondroplasia.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 18,905 | -0,42 % | Arrowhead Pharmaceuticals CEO verkauft Aktien im Wert von 246.109 US-Dollar | ||
| IOVANCE BIOTHERAPEUTICS | 7,072 | -1,31 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen | |
| ARDELYX | 4,386 | -0,36 % | Ardelyx (NASDAQ:ARDX) Shares Gap Up After Insider Buying Activity | ||
| SWEDISH ORPHAN BIOVITRUM | 27,440 | +0,96 % | Swedish Orphan Biovitrum AB: Bulletin from Sobi's Extraordinary General Meeting (EGM) | STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals... ► Artikel lesen | |
| INSMED | 67,50 | +2,27 % | Insmed-CEO William Lewis verkauft Aktien im Wert von 1,79 Millionen US-Dollar | ||
| BENITEC BIOPHARMA | 11,585 | +0,04 % | Benitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update | -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical... ► Artikel lesen | |
| SCHOLAR ROCK | 42,600 | +0,47 % | Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic... ► Artikel lesen | |
| PROQR THERAPEUTICS | 2,450 | -4,74 % | ProQR Therapeutics Aktie: Weg in die Zukunft geebnet! | ProQR Therapeutics, ein niederländisches Biotechnologieunternehmen, zeigt sich trotz herausfordernder Marktbedingungen widerstandsfähig. Die Aktie verzeichnete am 2. November 2024 einen leichten Rückgang... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 2,255 | -0,66 % | Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease | SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address... ► Artikel lesen | |
| THERATECHNOLOGIES | 1,640 | +2,50 % | Theratechnologies Inc. - 6-K, Report of foreign issuer | ||
| CRINETICS PHARMACEUTICALS | 52,00 | 0,00 % | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 10,150 | +1,70 % | Ensysce Biosciences Inc.: Ensysce Biosciences Regains Full Compliance with Nasdaq | SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 9,710 Euro und damit -0,41 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.
